Merus to Participate in Upcoming Investor Conferences
- BMO Biopharma Spotlight Series: Oncology Day (fireside chat):
Wednesday, November 8at 11:30-11:55 a.m. ET(No live webcast, replay will be available after the event)
- Stifel 2023 Healthcare Conference (fireside chat):
Tuesday, November 14at 1:15-1:45 p.m. ET(Live webcast available contemporaneously)
Archived presentations will also be available on the Investors page of the Company's website for a limited time after the event.
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and twitter.
Multiclonics®, Biclonics® and Triclonics® are registered trademarks of Merus N.V.
Investor and Media Inquiries:
Sherri SpearMerus N.V. VP Investor Relations and Corporate Communications 617-821-3246 firstname.lastname@example.org Kathleen FarrenMerus N.V. IR/Corp Comms 617-230-4165 email@example.com